Published in Virus Weekly, September 12th, 2006
In an oral presentation, researchers reported data from patients who had reached 48 weeks of treatment in an ad hoc (unplanned) pooled analysis from the POWER 1 and POWER 2 studies.
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Prezista, a protease inhibitor formerly known as TMC114, in June 2006. Prezista, co-administered with 100 mg ritonavir (Prezista/rtv) and with other antiretroviral agents, is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.